rdESAT-6 is a recombinant Mycobacterium tuberculosis specific antigen used to detect a Mycobacterium tuberculosis infection. A drug used during a diagnostic test to detect tuberculosis infections.
- Mechanism
- Curator reviewed · 1 reference
rdESAT-6 is a recombinant Mycobacterium tuberculosis (M. tuberculosis) specific antigen that is administered intradermally with rCFP-10 to detect Mycobacterium tuberculosis infections. In case of an infection with M. tuberculosis, the combination of these two antigens induces a delayed-type hypersensitivity reaction directed by cytokines, which are released by thymus helper cells type 1: This reaction is seen as an induration at the site of injection. The induration reaches its maximum 48 to 72 hours after administration.
- Primary indication
- rdESAT-6 is indicated as a diagnostic aid for detection of Mycobacterium tuberculosis infection, including disease, in adults and children aged 28 days or older.Curator reviewed · 1 structured indication
- First approval
- European Union, 2025
- Also known as
- Mycobacterium tuberculosis early secretory antigenic target
What you can answer from here — as of August 23, 2025
Which other approved drugs treat the same conditions as rdESAT-6, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account